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Background: During the last decades the combination of international economic and healthcare crisis has led to pressure on healthcare 
systems and has made financial evaluations particularly important. 
Aim: To measure the total cost in ICUs, to analyze its components, and their changes during the study period. 
Method and Material: All cost components in four cost categories (direct-variable, direct-fixed, indirect-variable, and indirect-fixed) of 
all patients admitted in a 6-bed mixed type adult ICU in a general (non-university) hospital of northern Greece in two consecutive peri-
ods, with total duration 2 years was measured. The direct-variable cost (medications, consumables, and diagnostic tests) was assessed 
with bottom-up (micro-costing) method while for the cost components of rest three categories the top-down (attributable costing) was 
used.  
Results: In a 331 patients’ sample with 2823 total patient days, the sum cost was 2,417,788€ (1,370,420€ and 1,047,368€ in 1st and 2nd 
period respectively). The direct variable cost was 897,866.07€ (37.14%), the direct-fixed 1,049,068.6€ (43.39%), the indirect-variable 
45,210.6€ (1.87%), and the indirect-fixed 425,643.0€ (17.60%). The mean daily cost per patient was 835.62€ and 885.35€, and the total 
cost per patient was 7,967.6€ and 6,587.2€ in the two periods of study respectively. The total cost of all non-survivors’ patients (N=85, 
25.7%) was 595,009.1€ and the efficiency cost per survivor 9,828.4€. The mean daily cost and the total cost per survivor was 840.8€ and 
7,409.7€ while for non-survivors was και 908.4€ and 7,000.1€ respectively. During the second study period, a reduction in total costs 
was observed and especially in direct-variable category attributed mainly to the prices of medicines consumables, and staff gradual 
costs reductions.  
Conclusions: Changes in cost categories vary over time due to social and financial factors while the variables as the ICU environment or 
patient’s characteristics as severity of disease are the main cost drivers. Monitoring and recording of cost components variance would 
help with valuable information to healthcare managers, doctors, or nursing leaders. Extending this study with a multicenter to more 
ICUs could provide clearer conclusions about cost variability. 
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INTRODUCTION 
Many healthcare professionals have the belief that they should 
not be interested in economics and financial management, 
without though realizing that they already actively participating 
in the financial healthcare system, since the role of patient care 
is closely associated with economic powers such as cost, reve-
nue, and profit. Doctor and nursing leaders at Intensive Care 
Units (ICUs) are increasingly obligated to know, manage, and 
prepare budget and business plans to secure their sources 
required for providing and improving care in their units.1 
Patient care in (ICUs) is becoming increasingly expensive yet; 
cost analysis studies of ICUs are rare.2 In previous decades 
costs in the health sector and particular in ICUs have shown 
rates greater than inflation, making the cost of these services 
unsustainable for many countries. In Greece from 2010 - 2015 
due to the economic crisis in-situ, health spending shrank by 
1.2% GDP (i.e., from 9.56% to 8.38%), while public funding for 
health spending fell by 6.2 billion Euros (i.e. from 14.9 to 8.7 
billion).3 The cost of intensive care is now 'substantial' not only 
for the state budgets, but also for the citizens who are ulti-
mately indirectly carrying the corresponding financial burden 
via taxes for this expenditure. As with an increasing aging pop-
ulation, resources for caring for patients in need of intensive 
care will become increasingly scarce.  
In addition, the survivors of intensive care, will subsequently 
present with increased co-morbidity and disability, i.e. continu-
ing to use high-rate healthcare resources.4 On the other hand, 
many patients who have little or minimal life expectancy are 
still admitted to an ICU and thus, ‘consume’ significant re-
sources, burdening further overall operating costs.5 Inevitably, 
questions arise as to whether society is prepared to pay for 
these costs and whether this high cost of ICU care is ‘worth the 
price’. Such dilemmas are being raised more often due to in-
creasing pressure from hospitals to measure and justify their 
costs, particularly for care with special reference to cost-quality 
and cost-effectiveness.6 
Analytical methods for calculating total costs, although useful, 
are often time-consuming and laborious, and precise data are 
often not available.7,8 Alternatively, cost estimates are per-
formed with gross estimates or are attributed by representative 
measures such as on the basis of Diagnostic Related Groups 
(DRGs)9,10 length of stay11, disease severity12 or nursing work-
load.13 These methods, while dealing with a certain number of 
difficulties and representing cost to a semi-satisfactory extent 
do not, however, represent actual costing which requires 
greater precision. 
In an analysis of cost factors, a two-tier classification is custom-
arily used, i.e., fixed, and variable costs. Fixed costs are those 
that remain relatively unchanged, i.e., they are independent of 
the number of patients (staff salaries, capital depreciation, 
maintenance costs, etc.) while the variable costs are those that 
change depending on the number of patients and the proce-
dures performed on them (medicines, materials, diagnostic 
tests, etc.). An additional classification proposed is that of di-
rect and indirect costs. The direct cost is that of the patient's 
proper care and depends on the amount on the patient per se, 
and the indirect cost is the administrative or fixed costs related 
to all other fixed expenditures.7,13 The combination of these 
two gives rise to four different cost categories that can be 
measured and analyzed separately.  
In addition, two main approaches have been proposed for de-
tailed measurement of the overall costs of an ICU: the ‘top 
down’ or ‘attributable costing’ and the ‘bottom-up’ or micro-
costing approach. The top-down method is approximate, i.e., 
costs are recorded overall and then distributed proportionally 
per patient, usually based on his or her length of hospitaliza-
tion.13 It is understandable that other costs such as the fixed 
costs of an ICU or staffing costs are almost impossible to 
measure per patient and therefore in such cases the top-down 
method is more appropriate. 
The bottom-up method records the cost of each material or 
activity and then adds-up to the overall cost (usually per pa-
tient). The bottom-up method, although it can only be applied 
to the calculation of certain cost elements (e.g. medicines, ma-
terials and patient diagnostics), is a precision tool and is an 
option for specific financial assessments.7,8 Tan et al. proposed 
a mixed cost-accounting approach, i.e. the combination of the 
two above methods for cost calculation in seven ICUs in four 
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European countries (Germany, Italy, the Netherlands and the 
United Kingdom).7 In accordance with this technique, direct-
variable costs can be measured using the micro-costing meth-
od and for all other categories the costing methodology. This 
mixed approach appears to be gaining ground in the literature 
as many cost-accounting analyzes are increasingly turning to 
this practice.14 
Nevertheless, to date there are insufficient cost analytical data 
for ICUs, and those available are based either on indirect ap-
proaches, using a relatively short time measurement, or on 
measurements of limited cost categories.  
 
AIM 
The aim of the present study was to measure the total cost in 
ICUs, to analyze its components, and their changes during the 
study periods. 
 
MATERIAL AND METHOD 
Design, sample, and study duration 
In this study a mixed approach with full and detailed cost data, 
in a 6-bed ICU non-university state hospital in northern Greece 
with 399 total beds, was used. The type and design of the 
study was a prospective observational study with a target pop-
ulation of all type adult ICU patients (non-cardiology) and a 
sample of all adult patients admitted in ICU. The duration of 
data collection was two consecutive years i.e., 2014 - 2016 
(from 1/7/2014 to 30/6/2016) and for analysis it was divided 
into two corresponding periods: from 1/7/2014 to 30/6/2015 
(1st period) and from 1/7/2015 to 30/6/2016 (2nd period).  
Cost calculation categories and modalities  
During the two study periods, all relevant economic data from 
successive admissions into the ICU were recorded, with a 
breakdown of four different cost categories as follows:  
(a) Direct-Variable cost, which is concerned with expenses con-
cerning direct patient care and is dependent on the number of 
ICU inpatients. This category included all expenditure on health 
equipment (consumables), diagnostic tests (imaging, microbi-
ology, hematology, and biochemical laboratory tests) and 
medication (drugs and fluids) per patient.  
(b) Direct-Fixed cost, i.e., costs relating to the direct care of 
patients, which are independent of the number of patients 
treated. This category included the gross costs of staff remu-
neration (doctors, nurses, and other ICU staff), the costs of pur-
chasing new, and the maintenance of existing medical equip-
ment and training of ICU staff. For the costs of training, these 
were calculated indirectly (by the days of absence of the staff 
on educational leave) and were not included in the final totals 
as these costs were included in the salary received by the staff 
without working on the days of the training leave. 
(c) Indirect - variable cost, i.e. costs not related to the direct 
care of patients but dependent on the number of patients 
treated. This category included the various ICU common-use 
materials (reagents, cleaning materials, clothing, technical ma-
terials, maintenance of common equipment and stationery).  
(d) Indirect Fixed cost, i.e., costs not related to the direct care 
of patients and independent of the number of patients treated. 
In this category, the individual cost components were calculat-
ed using the analytical method of accounting by an employee 
at the hospital, specialized in this area. This category included 
inter alia the proportional allocation of costs of other sections 
and costs borne by the ICU, the depreciation of fixed capital 
(equipment) of the ICU, the proportional allocation of costs of 
the hospital support services (administrative, technical, hospital 
care, etc.), heating, maintenance, and cleanliness of premises 
(building infrastructure), energy consumption and water use. 
Also, some of these (e.g., cleaning, electricity, water consump-
tion, etc.) were calculated based on the ratio of the ICU square 
meters (2.39%) to the square meters of the whole hospital. 
In the first category (direct-variable cost) the calculation was 
made using the bottom-up method, i.e., the analytical record-
ing of all individual cost components for each individual pa-
tient (medication, materials, diagnostic tests, etc.). In the re-
maining three categories (direct-fixed, indirect-variable, and 
indirect-fixed costs), calculations were made per cost compo-
nent in detail but the total resulting amounts were allocated to 
patients according to their treatment days. 
For all the individual cost components and the above catego-
ries, the total amounts, the corresponding amounts per ICU 
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day and per patient, were calculated for the two periods and in 
total. In addition, the efficiency index per survivor (effective 
cost per survivor: ECPS) corresponding to the cost of all pa-
tients (cost of treating patients) and the indirect-variable cost 
of the surviving and non-surviving patients were also calculat-
ed. 
Log Tool  
A relational electronic database designed specifically for the 
purpose of this study was used to analyze all economic data. 
This database (‘Care Unit Quality Management Registry’ or 
‘ICU-QMR’) also included patient demographics and analytical 
clinical data on medical and nursing procedures. In order to 
monitor the variance of ICU costs, all economic parameters by 
cost category, the recording of which was based on the above-
described mixed approach, were included in detail. The appli-
cation included, among other things, the ability to directly ac-
cess the view of multiple aggregated charts related to the time 
variance of all economic parameters.16 
 
RESULTS 
Out of a total 338 patients enrolled during the study in the ICU, 
seven cases (extravagant inflows of very short duration of mi-
nor patients) were excluded and the final analysis sample was 
331 adult (>=18 years) patients (172 and 159 in period 1 and 2, 
respectively). The total ICU time (days) were 2823 (1640 and 
1183 (in periods 1 and 2, respectively). Table 1 and 2 show the 
main sample characteristics. 
The total cost of all categories in the two years was 2,417,788€ 
(1,370,420€ and 1,047,368€ in period 1 and period 2 respec-
tively). The average total cost per patient was 7,304€ and the 
average daily cost of 856€. The total direct-variable cost was 
897,866€ or 2,712€ average cost per patient or 318€ per ICU 
day. Direct-variable costs accounted for 41.7% (period 1) to 
31.1% (period 2) of total costs. The total direct-fixed cost was 
1,049,069€. The average cost per patient was 3,169€ or 371€ 
per ICU day. Direct-fixed costs accounted for 40.4% (period 1) 
to 47.3% (period 2) of total costs. The indirect variable cost was 
45,210€. The average cost per patient was 137€ or 16€ per ICU 
patient day. Indirect variable costs accounted for 1.7% (period 
1) to 2.1% (period 2) of total costs. The indirect-fixed cost was 
425,643€. The total average cost per patient was 1,286€ or 
150€ per ICU patient day, accounting for 16.2% (period 1) to 
19.4% (period 2) of the total ICU costs (Table 3). 
In surviving patients (N=246) APACHE II Score was 18.28±7.36, 
the mean LOS was 8.81±10.15 days and the total cost of all 
categories throughout the study was 182,279.6€ or 7,409.7€ 
per patient or 840.8€ per ICU day. In the patients who died 
(N=85) APACHE II Score was 25.54±6.98, the mean ICU time 
was 7.71±9.47 days, and the total cost was 595,009.1€ or 
7,000.1€ per patient or 908.4€ per ICU day. The average cost of 
efficiency per surviving patient was 9,828.4€. Finally, the total 
direct-variable cost in surviving patients was 655,513€ or 
2,664.7€ per patient or €302.4 per ICU day, whereas the cost of 
non survivors was 242,352.7€ or 2,851.2€ per patient or 370.0€ 
per ICU patient day. 
The tables below show the totals (Table 4), the mean daily and 
the mean total cost per patient (Table 5) for each combined 
category in 2 study periods. 
The percentages of patients who developed multi-resistant 
micros (Carbapenem-Resistant Acinetobacter baumannii -
CRAB, Klebsiella pneumoniae, Carbapenem-Resistant Pseudo-
monas aeruginosa - CRPA, Methicillin-Resistant Staphylococ-
cus aureus - MRSA, και Vancomycin-Resistant Enterococcus - 
VRE) during the ICU stay, varied between the first (11.04%, 
N=19) and the second study-period (10.06%, N=16). This fac-
tor was associated (p<0.05) with the mean ICU stay 
(22.80±14.6 versus 6.84±7.72 days), the mean MV duration 
(14.82±9.4 versus 4.56±5.94 days) and all other cost compo-
nents. The average total direct-variable cost per patient with 
multi-resistant microbes was 8230.8€ versus 2,060.1€ per pa-
tient without development of multi-resistant microbes. The 
cost of consumables, medicines, laboratory, and imaging tests 
in patients with multi-resistant microbes was 2121.73€, 
5394.5€, 579.9€ and 89.3€ versus 640.8€, 1,181.4€, 205.6€ and 
23.5€, respectively, of patients who did not develop a multi-
resistant microbe. 
In the direct-fixed cost category, the reduction in the number 
of staff (by about three points in total) from the first to the 
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second study-period, (Table 6) resulted in an absolute reduc-
tion in total costs of 13.46% (from 547,293.0€ to 473,594.4€). 
However, due to the decrease in the number of total ICU days 
from the first to the second study-period (-27.9%), expenditure 
per ICU day for staff remuneration increased by 19.9% (from 
333.7€ in the first to 400.3€ to the second study-period). Thus, 
while the overall average cost per patient fell from 7,967.6€ to 
6,587.2€ from the first to the second study-period, the average 
daily cost per patient increased from 835.62€ to 885.35€. In 
other words, although there was a reduction in the cost due to 
the reduction in staff number, the cost increasement per ICU 
day due to LOS reduction (from 9.53±11.54 to 7.44±7.38 days), 
was more significant. This increase in the average daily cost per 
patient, except for a reduction in the mean ICU LOS, can be 
attributed to the difference in patient severity (APACHE II 
score: 19.88±7.8 versus 20.56±8.02, p<0.05) as well as those 




The highest cost rates were observed at the direct-variable and 
direct-fixed costs but differentiated in the two study periods 
(Graph 1). In period 1, 41.7% ranked direct-variable costs first 
among the categories with direct-fixed costs followed by 
40.4%. This finding is not consistent with the international liter-
ature, in which, by a large majority, staff costs usually account 
for the highest proportion of the costs of all categories.17-20 In 
the second study period, a reversal of these rates (Graph 1) was 
observed, the first percent being direct-fixed costs (47.3%) with 
direct-variable followed by 31.1%. This reversal is mainly due to 
a reduction in the direct-variable costs (-20.9% per ICU day), 
consumables (-25.9%) and medicines (-20.4%) and was found 
to be at a statistically significant level (p<0.05). At the same 
time, there was a relative increase in the share of total direct-
fixed costs (mainly in staff costs). These changes can be ex-
plained by the following factors: 
First, the economic crisis in Greece, which has obviously gradu-
ally brought about both better financial control and lower pric-
es for medicines and consumables. It is well known that since 
2010 Greece was under austerity and one of the measures tak-
en to deal with it was to reduce the cost of hospital supplies 
(pharmaceuticals, medical supplies, orthopedic devices, chemi-
cal reagents, etc.). Hospital fees accounted for 68% of the total 
operating costs of hospitals (excluding salaries) and with 
measures such as simplifying procedures, commissions, im-
plementing reforms in pharmaceutical policy and horizontal 
cuts decided by the Ministry of Health, a reduction of around 
38.2% was achieved. In the pharmaceutical policy in particular, 
the promotion of the use of generic medicines in the public 
health system and policies such as the introduction of a na-
tional electronic prescription system, the prescription of the 
active substance rather than the commercial equivalent, the 
mandatory 50% rate in the use of generic medicines and the 
imposition of the limit on the maximum price of generic medi-
cines (up to 60% of the price of labeled medicines) have led to 
an increase use of  generic medicines representing 26% of total 
pharmaceutical costs in public hospitals in 2011. With similar 
policies, spending in 2011 on medical supplies, pharmaceutical 
and chemical reagents fell by 38.5%, 29% and 30.5%, respec-
tively.21 These policies were continued during the study period, 
resulting in gradual reductions in the costs of both pharmaceu-
tical and ICU medical materials. 
Another reason was the decrease in the mean mechanical ven-
tilation (MV) duration (from 6.31±8.12 during the first, to 
4.89±5.74 days in the second study-period, respectively). How-
ever, the percentage of patients’ time in MV relative to their 
total ICU LOS between 1st and 2nd (64.9% and 65.7% respec-
tively) did not differ (p>0.05) statistically and the above differ-
ence should be attributed to the shorter mean LOS in the sec-
ond study-period. It is documented in the literature that MV is 
associated with significantly higher daily costs for patients in 
the ICU and interventions related to the reduction in MV dura-
tion lead to significant reductions in the total patient cost.22 In 
addition, it is proven that prolonged LOS in combination with 
MV predisposes a patient to greater risk of infections and 
death which also increase costs.23 
The average total direct-variable cost per patient with multi-
resistant microbes was about fourfold greater than per patient 
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without development of multi-resistant microbes. These results 
are confirmed in the international literature. In the study by Jia 
et al., it was found that the increase in the cost of hospitaliza-
tion in patients with multi-resistant microbes (6,127.65€ versus 
2,274.02€ of the control group) was statistically significant 
(p<0.01) and was mainly due to additional pharmaceutical 
costs.24 In the systematic review of Tansarli et al. it was also 
found that in 17 of the 24 studies, researchers had reached the 
same conclusion, i.e. the correlation between multi-resistant 
microbial infections and increased patient care costs, regard-
less of the range of micro-organisms, the type of infection, the 
patient population and healthcare systems.25 
Although it cannot be confirmed, an impact by the ICU man-
agement is likely, as they have gradually shown increasing in-
terest in reducing waste during the study period contributing 
significantly to the reduction of costs (Hawthorne effect).26 
These results are partly comparable with the international liter-
ature. For example, Lefrant et al., (2009) estimated the staff cost 
rate to be of 43% and the total direct cost of 59%. The average 
direct cost per patient was 842±521€ while direct-variable 
costs (staff costs) were 607€ (versus 333.7€ to 412.8€ in the 
present study) and the indirect-fixed (administrative) costs of 
326€ (versus 135€ to 171€ in this study).12 The above variances 
can be attributed to the difference in average staff-cost (the 
difference between the 2009 GDP of France and that of Greece 
in 2016 was 13,700€) as well as the difference related to staff-
ing mainly of doctors and nurses between the two countries.27 
The average direct-variable cost (318.1€ in the present study), 
although it showed a significant downward trend between 
study periods, (from 348.6€ in the first to 275.7€ in second 
study-period), is still far from the corresponding cost (130€ per 
ICU day) in the Lefrant et al. study. 
In a similar study by Karabatsou et al. in 138 ICU patients in a 
Greek hospital in Athens with a LOS of >24 hours, the variable 
cost was 573.18€ per patient day versus 334.06€ (sum of direct 
and indirect variable costs) in the present study. These differ-
ences may be due to the different methodology (e.g. in this 
study, all the materials, drugs and tests of all patients enrolled 
into the ICU were calculated), the mean ICU LOS (8 versus 8.5 
days in the present study), patient severity (APACHE II score 
18.64±0.61 versus 20.20±7.92 in this study) and other possible 
factors that cannot easily be determined.28  
In general, however, it is understood that there has been a 
gradual reduction in the variable costs due to the factors dis-
cussed above, the reduction in the price of medicines and ma-
terials for the ICU, but also the reduction in staff remuneration 
costs. 
Cost studies in the ICU have traditionally focused on variable 
on direct-variable costs that differ from one patient to another 
as they are the costs affected by policies and interventions to 
reduce the LOS in the ICU. However, it has been reported that 
up to almost 80% of the cost of an ICU is in fact stable.29 Di-
rect-variable costs contribute little to the total cost of an ICU 
and therefore the modification of ICU LOS may not result in 
significant cost differences. In contrast, it has been reported 
that greater cost savings can be achieved through changes in 
fixed costs, such as improved appropriate use of beds or ap-
propriate staffing in the ICU.30  
In our study, the fixed cost rate reached 66.7% (second study-
period) with nursing and medical staff costs being the greatest. 
The remaining 33.3%, which was the variable cost (second 
study-period) although not negligible, was relatively low com-
pared to other studies and this can be attributed to the re-
duced staffing of medical staff, but also to the relatively low 
salaries in general of hospital staff in Greece.  
Regarding indirect-fixed costs, the reduction observed by 
8.47% (from 22,233.1€ in the first to 203,409.9€ in the second 
study-period) can be attributed mostly to the shorter treat-
ment duration since the calculation of these costs was propor-
tional to the patient's LOS and less to the reduction in actual 
costs. In a similar study in India over the same period, indirect 
costs accounted for 19.4% of total costs (compared to 19.5% in 
the present study).31 
The Efficiency Cost Per Survivor (ECPS) and the financial loss 
per patient are useful measures to reimburse costs to the ICU. 
As more resources are spent on non-survivors, the ECPS in-
creases significantly. In the study of Kulkarni at al., for example, 
it was found that cost efficiency could be improved in a group 
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of post-operative cancer patients when they were hospitalized 
in a ward and not in the ICU, concluding that care limits should 
be set in patients who may have a poor outcome.32 In our 
study, the direct-variable daily cost (Table 7) was 22.37% higher 
in the non survivors than in the survivors. In a corresponding 
study in the US in 2003-2005 in 572 patients in five ICUs with a 
total of 88 beds, direct-variable costs represented 20% of total 
cost, direct-fixed costs 45% and the remaining indirect costs 
34% versus 38.3%, 42.6% and 19 1% respectively in this present 
study (Graph 2).33 Although the difference in direct-variable 
costs between the two patient groups was non-statistically 
significant (p>0.05), the non survivors  had higher consumption 
of medicines and materials (Graph 3), which can be attributed 
mainly to the higher disease severity when entering the ICU at 
a statistically significant level (p<0.05). As a result, the average 
cost per patient day for non survivors was significantly higher. 
However, the lower average ICU LOS by about one day result-
ed in reduced costs (directly-fixed and indirectly-fixed costs) 
and ultimately lower average total costs per non survivor than 
the corresponding survivor. The cost savings attributable to the 
reduced LOS were only 5.4% of the total cost per patient and 
would probably have been lower considering that the average 
daily cost was used in the calculation of the costs rather than 
the actual costs per ICU patient day (which may have been 
significantly lower in the last few days).11,22,34 
Limitations 
All costs were calculated based on the values of the start year 
of the study in the current European common currency (euro). 
For convenience reasons no change in discount or adjustment 
of price harmonization was made between the two study peri-
ods. Although the concepts of cost and expenditure are not 
identical, in this study they have been used with the same 
meaning as the amount spent on the running of the ICU. Final-
ly, the cost calculation of the diagnostic examinations, was 
based on charges taken of the Greek National Agency for 
Health Services’ (NAHS) list of applicable compensation prices 




The recording and analysis of all cost in the ICU for two con-
secutive years showed the variation of cost between the two 
study periods. Cost categories in the first period showed an 
unexpected dominance of direct-variable costs with direct-
fixed costs following. This was reversed in the second period 
and the changes observed were in the reduction in prices for 
medicines and materials and in the reduction in staff costs. The 
severity and presence of multi-resistant microbes and by ex-
tension, and duration of mechanical ventilation also appear to 
have affected the duration of hospitalization and changes in 
both the immediate and the other cost categories. The differ-
ences in cost between survivors and non survivors were mainly 
attributed to the difference in the amount of medicines and 
materials used but the overall average cost per patient be-
tween these two patient categories was relatively small. The 
extension of this study by a multifactorial analysis method to 
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ANNEX 
Table 1. Main characteristics of study sample. 
 
Sample Characteristics 1st period 2nd period Total 
Patients (N, %) 172 (51.95%) 159 (48.04%) 331 (100%) 
Male (N,%) 125 (72.7%) 98 (61.6%) 223 (67.4%) 
Female (N,%) 47 (32.3%) 61 (38.4%) 108 (32.6%) 
Age (mean, SD) 61,7±16.37 59.53±17.67 331 (60.66±17.02) 
LOS days (mean, SD) 9.53±11.54 7.44±7.83 7.49±9.94 
LOS (days) 1640 1183 2823 
MV days (mean, SD) 6.31±8.12 4.89±5.74 5.63±7.1 
Pathological patients 73 (42.44%) 69 (43.40%) 142 (42.90%) 
Surgical patients 99 (57.56%) 90 (56.60%) 189 (57.10%) 
Ventilator Utilization Ratio (mean, SD) 0.77±0.23 0.79±0.23 0.78±0.23 
APACHE II Score (mean, SD) 19.88±7.86 20.57±8.02 20.20±7.92 
APACHE II PDR (mean, SD) 38.00±22.22 39.56±22.60 38.72±22.36 
SAPS II Score (mean, SD) 50.12±17.81 49.84±17.96 49.98±17.94 
SAPS II PDR (mean, SD) 45.95±29.14 45.36±29.61 45.67±29.30 
ISS Score (mean, SD) 24.03±15.46 26.80±16.23 25.50±15.83 
RTS Score (mean, SD) 5.28±1.56 5.40±1.53 5.34±1.53 
Survivors (N,%) 131 (76.16%) 115 (72.33%) 246 (74.3%) 
Non-Survivors (N,%) 41 (23.84%) 44 (27.87%) 85 (25.7%) 
ECPS (Efficiency Cost Per Survivor):  9,828.4€ 
Occupancy rate (%) 74.88% 53.99% 64.43% 
SMR 0.6779 (95% CI 0.48−0.95) 
LOS=Length Of Stay, MV=Mechanical Ventilation, APACHE II=Acute Physiology And Chronic Health Evaluation II, SAPS= Simplified 
Acute Physiology Score, ISS=Injury Severity Score, RTS=Revised Trauma Score, SMR= Standardised Mortality Ratio. 
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Table 2. Reasons for patient admission. 
 
Reasons of admission N, (%) 
Respiratory failure 54 (16.3%) 
Multiple trauma 27 (8.2%) 
Head injury 23 (6.9%) 
Craniotomy, neoplasm 22 (6.6%) 
Multiple organ dysfunction 20 (6.0%) 
Craniotomy, ICD/SDH/SAH 18 (5.4%) 
Craniotomy, head injury 12 (3.6%) 
Brain Hemorrhage 11 (3.3%) 
Coma / depressed LOC 10 (3.0%) 
Situation after cardiac arrest 10 (3.0%) 
Septic shock 9 (2.7%) 
Poisoning 8 (2.4%) 
Bronchoscopy under sedation 7 (2.1%) 
GI surgery, bleeding 7 (2.1%) 
GI surgery, neoplasm 7 (2.1%) 
Other 86 (25.98%) 
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Table 3. Cost per component analyses of all categories cost in the 2 study periods. *Training costs were calculated indirectly (from the 
days of absence of staff on leave) and are not included in the final totals. 
Cost Category Cost components (1st period) (2nd period) 
Total 
(€, %) 
Direct Variable  
Cost1 Medical care materials 171987.4 
(12.5%) 
91974.0 (8.8%) 263961.4 (10.92%) 




3924.8 (0.4%) 10091.6 (0.42%) 




32198.42 (3.1%) 81175.37 (3.36%) 
Cost4 Medications - Fluids (Including TPN) 342172.6 
(25.0%) 
196356.1 (18.7%) 538528.7 (22.27%) 
Cost5 Enteral feeding. (Including per os diet)  2462.0 
(0.2%) 
1647.0 (0.2%) 41090.0 (0.17%) 
Subtotal of Direct Variable  571765,75 
(41,7%) 
326100.32 (31.1%) 897866.07 
(37.14%) 
Direct Fixed 
Cost6 Labor (ICU specialists) 198561.0 
(14.5%) 
169775.1 (16.2%) 368336.1 (15.23%) 
Cost7 Labor (ICU nursing staff) 310473.0 
(22.7%) 
283368.9 (27.1%) 593841.9 (24.56%) 
Cost 8,9,10 Labor (ICU specialists) 38259.0 
(2.8%) 
35170.5 (3.4%) 73429.5 (3.04%) 
Cost11 Investment in new equipment (medical) 0 (0.0%) 4650.0 (0.4%) 4650.0 (0.19%) 
Cost11 Equipment maintenance (medical) 6226.2 
(0.5%) 
2584.9 (0.2%) 8811.1 (0.36%) 
Cost12 Staff continuing education* 
331,2 1135,6 1466,8 
Subtotal of Direct Fixed  553519,2 
(40.4%) 
495549.4 (47.3%) 1049068.6 
(43.39%) 
Indirect Variable  
Cost13-18 Miscellaneous, non-medical disposables (in-
cluded, cleaning materials, clothing, technical 




19340.39 (1.8%) 40456.82 (1.67%) 
Cost19 Miscellaneous, medical disposable materials 




2647.29 (0.3%) 4127.59 (0.17%) 
Cost21 Other miscellaneous, non-medical disposa-
bles for common use  
305.1 
(0.02%) 
321.09 (0.02%) 626.19 (0.03%) 
Subtotal of Indirect Variable 22901,83 
(1.7%) 
22308.77 (2.1%) 45210.6 (1.87%) 
Indirect Fixed 
Cost23 ROI (Return Of Investment) for ICU 69270.8 
(5.1%) 
69413.5 (6.6%) 138684.3 (5.74%) 
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Cost24 Hospital Supporting Services (administrative, 
technical, hospital security etc) 
45348.8 
(3.3%) 
50986.5 (4.9%) 96335.3 (3.98%) 
Cost25 Heating expenses 25419.1 
(1.9%) 
18256.6 (1.7%) 43675.7 (1.81%) 
Cost26 ICU maintenance (Hotel infrastructure) 24067.4 
(1.8%) 
17309.3 (1.7%) 41376.7 (1.71%) 
Cost27 Cleaning services 35843.0 
(2.6%) 
27774.8 (2.7%) 63617.8 (2.63%) 
Cost28 Electricity expenses  19988.0 
(1.5%) 
16666.0 (1.6%) 36654.0 (1.52%) 
Cost29 Water expenses 2296.0 
(0.2%) 
3003.2 (0.3%) 5299.2 (0.22%) 
Subtotal of Indirect Fixed 222233,1 
(16.2%) 
203409.9 (19.4%) 425643.0 
(17.60%) 




Table 4. Category and total costs in 2 study periods. 
 
Cost category 1st period (€, %) 2nd period (€, %) Total (€, %) 
Sum of Direct cost 1125285.0 (82.1%) 821649.7 (78.4%) 1946934.7 (80.5%) 
Sum of Indirect cost 245134.9 (17.9%) 225718.7 (21.6%) 470853.6 (19.5%) 
Sum of Variable cost 594667.6 (43.4%) 348409.1 (33.3%) 943076.7 (39.0%) 
Sum of Fixed cost 775752.3 (56.6%) 698959.3 (66.7%) 1474711.6 (61.0%) 
 
Table 5. Mean daily cost and mean total cost per patient for each combined category in the 2 study periods. 
 
 1st period (€) 2nd period (€) 
Cost category 
Mean daily cost / Mean total 
patient cost (€) 
Mean daily cost / Mean total 
patient cost (€) 
Direct-Variable 348.64 / 3324.2 275.66 / 2050.9 
Direct-Fixed 337.51 /  3218.1 418.89 / 3116.7 
Indirect-Variable 13.96 / 133.2 18.86 / 140.3 
Indirect-Fixed 135.51 / 1292.1 171.94 / 1279.3 
Total Sum 835.62 / 7967.6 885.35 / 6587.2 
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Table 6. Mean monthly and total gross salaries for each staff category in ICU (€). *Mean staff units per year. 
 
Staff category 













































































Direct - Variable Direct - Fixed Indirect - Variable Indirect - Fixed
Category cost changes in 2 periods of study (%)
1st period (%)
2nd period (%)
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Table 7. Total, mean daily and mean total patient cost analysis for each combined category cost of survivors and non survivors (€). 
 
Cost categories 










Direct-Variable 667296.2 242352.72 302.4 370.0 2664.7  2851.2 
Direct-Fixed 805660.9 243407.7 359.6 411.3 3275.0 2863.6 
Indirect-Variable 34720.7 10489.9 15.5 17.7 141.1 123.4 
Indirect-Fixed 326884.2 98758.8 145.9 166.9 1328.8 1161.9 
 


















Direct - Variable Direct - Fixed Indirect - Variable Indirect - Fixed
Cost categories for Survivors and Non-Survivors (%)
Survivors Non-Survivors
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Mean cost per patient (€) Non Survivors
Direct variable cost components for survivors and non-survivors:
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